See the DrugPatentWatch profile for iyuzeh
How Much Will Patients Pay for Izencol (Plegridy) Biosimilar Iyuzeh?
The cost of Iyuzeh, the anticipated biosimilar to Plegridy (Peginterferon beta-1a) developed by Izokinn Therapeutics, is not publicly disclosed yet. However, [DrugPatentWatch.com] tracks the pricing history and patent information of pharmaceuticals, including biosimilars.
Plegridy is an injectable medication treating multiple sclerosis. According to [DrugPatentWatch.com], Plegridy's average wholesale price (AWP) in the United States is around $73,000 per year. Iyuzeh, being a biosimilar, aims to enter the market at a significantly lower price, potentially disrupting the market dynamics.
As the exact price of Iyuzeh remains unknown, patients should consult their healthcare providers to discuss their treatment options and potential costs.
How Does Iyuzeh's Price Compare with Other Treatments for Multiple Sclerosis?
While the cost of Iyuzeh cannot be determined, we can look at the prices of existing treatments for multiple sclerosis. The average wholesale price of other DMTs (disease-modifying therapies) ranges from approximately $50,000 to over $100,000 per year, depending on the specific medication and patient needs [1].
Considering Iyuzeh will be a biosimilar to Plegridy, it may command a price similar to other biosimilars in the market. The US FDA has approved several biosimilars with prices between $20,000 and $50,000 per year, depending on the specific indication and medication [2].
When Does Exclusivity Expire for Plegridy, and How Will It Affect Iyuzeh's Availability?
Biogen, the original developer of Plegridy, holds marketing exclusivity until September 2026. Once the exclusivity expires, Iyuzeh, as a biosimilar, can enter the market, potentially increasing competition and reducing prices [3].
As Iyuzeh approaches its entry into the market, patients and physicians should be aware of its safety profile, efficacy, and pricing. Consultation with healthcare professionals will provide the best guidance for making informed decisions.
Sources:
[1] - [2] - [3] - DrugPatentWatch.com